Cumberland Pharmaceuticals Announces NDA Filing Plan for Ifetroban Following Share Price Decline
Cumberland Pharmaceuticals (CPIX) has announced its intention to file a New Drug Application (NDA) for ifetroban, a candidate treatment for cardiomyopathy associated with Duchenne muscular dystrophy. This announcement follows a significant single-day share price drop of approximately 49% during Monday's trading session. The company confirmed it recently completed a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway. The move aims to provide clarity on the development timeline for its key drug candidate following recent market volatility.
Tickers: $CPIX
Topics: Cardiomyopathy Duchenne muscular dystrophy FDA meeting NDA filing